Skip to main content

Branded

  • Avalere: Rising coinsurance means less certainty on cost for Medicare PDP beneficiaries

    WASHINGTON — Medicare Part D plan (PDP) beneficiaries might be paying more out of pocket for a majority of their prescription medication, according to a new analysis from Avalere Health. The company found that a majority — 58% of covered drugs among PDPs — of medications are subject to coinsurance rather than copayments for beneficiaries. In 2014, only about 35% of covered drugs were subject to coinsurance. 
     

  • Lupin completes Gavis acquisition

    MUMBAI and BALTIMORE — Lupin announced Wednesday that it had completed its acquisition of Gavis, which includes Gavis Pharmaceuticals and Novel Laboratories, for about $880 million. 
     
    Lupin said the acquisition will grow the company’s footprint in the U.S. generics market and expands its dermatology, controlled substance product and high value and niche generics pipeline. With the acquisition, Lupin also gains its first manufacturing site in the United States — Gavis’ New Jersey manufacturing facility. 

  • FDA, Amarin reach settlement on off-label use promotion

    NEW YORK — Amarin announced Wednesday that New York’s Southern District Court had approved its proposed settlement with the Food and Drug Administration, reached Tuesday, over the promotion of off-label use for its Vascepa (icosapent ethyl) capsules. 
     

  • CMS plan to boost MTM gains traction in Congress

    “Better care, smarter spending, healthier people.”

  • CVS Health to offer naloxone without prescription in 23 states by month's end

    WOONSOCKET, R.I. - CVS Health announced Monday that it will expand access to the opioid overdose-reversal medication naloxone at the end of March at its CVS Pharmacy locations in eight new states, including: Connecticut, Kentucky, Maryland, North Carolina, New Hampshire, Ohio, Virginia and Vermont.  
     
    Under a physician-approved protocol permitted by the state, CVS Pharmacy will be able to dispense naloxone to patients in these states without the need for an individual prescription.
     

  • TherapeuticsMD launches Rx prenatal that's certified vegan and certified kosher

    BOCA RATON, Fla. - TherapeuticsMD recently announced the launch of vitaMedMD's newest prescription prenatal multivitamin, vitaTrue, adding to its prenatal line consisting of vitaPearl, vitaMedMD One Rx, vitaMedMD Plus Rx and vitaMedMD RediChew Rx. 
     

  • Chrono Therapeutics shares clinicals supporting wearable smoking cessation device

    CHICAGO - Chrono Therapeutics on Friday announced that clinical data for the company's smoking cessation technology showed a statistically significant reduction in nicotine cravings in a trial of adult male smokers. The data were presented at the Society for Research on Nicotine & Tobacco's 22nd Annual Meeting.
     

  • FDA approves expanded Imbruvica indication

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new indication for Janssen Biotech’s and Pharmacyclics’ Imbruvica (ibrutinib) capsules, the companies announced Friday.
     
X
This ad will auto-close in 10 seconds